1
/
of
1
Iritero (Irinotecan)
Iritero (Irinotecan)
Regular price
₱2,880.00 PHP
Regular price
Sale price
₱2,880.00 PHP
Taxes included.
Quantity
Couldn't load pickup availability
Iritero (Irinotecan) is a potent topoisomerase I inhibitor chemotherapy medication designed to combat advanced cancers by disrupting DNA replication in rapidly dividing cells. This intravenous chemotherapy agent works by binding to topoisomerase I enzymes, preventing the unwinding of DNA strands essential for cell division and forcing cancer cells into apoptosis.
Primarily indicated for metastatic colorectal cancer, Iritero is frequently administered as part of the FOLFIRI regimen—combining irinotecan with 5-fluorouracil and leucovorin for enhanced efficacy. The medication also demonstrates clinical utility in small cell lung cancer and serves as a component in various combination chemotherapy protocols for solid tumors across multiple cancer types.
As a prescription-only chemotherapy agent, Iritero requires strict medical supervision and careful patient selection. The medication is contraindicated in patients with hypersensitivity to irinotecan components, active inflammatory bowel disease, bowel obstruction, severe bone marrow suppression, or pregnancy and lactation due to significant teratogenic and embryotoxic risks.
Dosing protocols are individualized based on patient factors, tumor type, treatment regimen, and prior therapy exposure. Healthcare providers calculate doses according to established chemotherapy guidelines and patient-specific parameters. Standard precautions include baseline blood count assessment, hepatic and renal function evaluation, and regular monitoring during treatment cycles.
Do not initiate Iritero without comprehensive medical consultation and oncology specialist guidance. This medication requires professional administration in certified healthcare settings with appropriate supportive care protocols in place.
Primarily indicated for metastatic colorectal cancer, Iritero is frequently administered as part of the FOLFIRI regimen—combining irinotecan with 5-fluorouracil and leucovorin for enhanced efficacy. The medication also demonstrates clinical utility in small cell lung cancer and serves as a component in various combination chemotherapy protocols for solid tumors across multiple cancer types.
As a prescription-only chemotherapy agent, Iritero requires strict medical supervision and careful patient selection. The medication is contraindicated in patients with hypersensitivity to irinotecan components, active inflammatory bowel disease, bowel obstruction, severe bone marrow suppression, or pregnancy and lactation due to significant teratogenic and embryotoxic risks.
Dosing protocols are individualized based on patient factors, tumor type, treatment regimen, and prior therapy exposure. Healthcare providers calculate doses according to established chemotherapy guidelines and patient-specific parameters. Standard precautions include baseline blood count assessment, hepatic and renal function evaluation, and regular monitoring during treatment cycles.
Do not initiate Iritero without comprehensive medical consultation and oncology specialist guidance. This medication requires professional administration in certified healthcare settings with appropriate supportive care protocols in place.
Share
